Two Drug Companies Unite for All-Oral Hep C Regimen | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

Nanogel Could Lead to Novel Hep C Vaccine

Back to News Homepage
Next

Finally, U.S. Takes Aim at Viral Hepatitis

Two Drug Companies Unite for All-Oral Hep C Regimen

The Editors at Hepatitis Central
July 8, 2011

Print this page

Focusing on an all-oral treatment, Pharmasset and Tibotec are working together to simplify and improve Hepatitis C treatment.

Pharmasset inks collaborative deal with J&J unit to develop hep C combo drug

July 6, 2011 by Brad Lemaire

Pharmasset (NASDAQ:VRUS) reported Wednesday it signed a collaboration agreement with pharmaceutical company Tibotec, a Johnson & Johnson (NYSE:JNJ) unit, to conduct clinical trials to develop an all-oral treatment for hepatitis C.

The study, which is slated to begin later this year, will assess the potential of Pharmasset’s drug PSI-7977, in combination with Tibotec’s TMC435, to achieve “sustained virologic response” 12 weeks post treatment, in patients infected with hepatitis C.

Princeton, New Jersey-based Pharmasset said the trial will also assess the safety and effects after 12 and 24 weeks of the combined treatment. Some patients will also take ribavirin in addition to PSI-7977 and TMC435.

Continue reading this entire article:
http://www.proactiveinvestors.com/companies/news/16090/pharmasset-inks-collaborative-deal-with-jj-unit-to-develop-hep-c-combo-drug-16090.html

No Comments - be the first!
Share
Share
Previous

Nanogel Could Lead to Novel Hep C Vaccine

Back to News Homepage
Next

Finally, U.S. Takes Aim at Viral Hepatitis

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.